Published in N Engl J Med on December 07, 1995
A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med (2002) 4.49
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 2.49
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr (2013) 1.46
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2002) 1.45
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol (1998) 1.27
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol (2001) 1.14
Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother (1998) 1.13
Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother (2000) 1.12
A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS (2008) 1.11
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J Virol (1998) 1.10
HIV-infected adolescents in southern Africa can achieve good treatment outcomes: results from a retrospective cohort study. AIDS (2013) 1.09
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1997) 1.00
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother (1997) 0.95
Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob Agents Chemother (1996) 0.93
Calpain regulates enterocyte brush border actin assembly and pathogenic Escherichia coli-mediated effacement. J Biol Chem (2003) 0.89
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect (1999) 0.87
A characterization of older AIDS patients in Maryland. J Natl Med Assoc (1998) 0.87
Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother (2007) 0.87
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process. Mol Biol Int (2012) 0.85
Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues. Antimicrob Agents Chemother (1997) 0.85
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. Antimicrob Agents Chemother (1997) 0.83
Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One (2013) 0.83
AIDS clinical trials. Is there access for all? J Gen Intern Med (1997) 0.82
Pediatric human immunodeficiency virus infection. Clin Microbiol Rev (1996) 0.81
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. AIDS Res Hum Retroviruses (2010) 0.80
Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1998) 0.78
Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses. Clin Diagn Lab Immunol (2001) 0.78
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. Onco Targets Ther (2015) 0.77
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother (2001) 0.77
Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother (1999) 0.77
Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol (1998) 0.75
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Antimicrob Agents Chemother (1998) 0.75
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl) (2015) 0.75
Investigational protease inhibitors as antiretroviral therapies. Expert Opin Investig Drugs (2016) 0.75
The role of HIV-proteinase inhibitors. Genitourin Med (1996) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Coverage by the news media of the benefits and risks of medications. N Engl J Med (2000) 7.50
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet (1997) 5.53
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod (2011) 5.49
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med (1992) 3.53
Promoting cost effective prescribing. BMJ (1995) 3.46
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis (2000) 3.12
Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Intern Med J (2005) 3.08
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Comparing treatments. BMJ (1995) 3.02
Estimating spatio-temporal receptive fields of auditory and visual neurons from their responses to natural stimuli. Network (2001) 2.85
Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med (1983) 2.72
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med (2000) 2.68
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ (1995) 2.61
Hepatitis B viral DNA molecules have cohesive ends. J Virol (1979) 2.61
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
The effects of information framing on the practices of physicians. J Gen Intern Med (1999) 2.52
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis (1999) 2.27
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Disease mongering: expanding the boundaries of treatable disease. Intern Med J (2008) 2.19
Restriction endonuclease cleavage map and location of unique features of the DNA of hepatitis B virus, subtype adw2. Proc Natl Acad Sci U S A (1979) 2.15
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ (1999) 2.11
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis (1999) 1.87
Autologous transfusion techniques: a systematic review of their efficacy. Transfus Med (2004) 1.84
Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1993) 1.82
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology (1998) 1.77
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ (1993) 1.76
Ethics and evidence based medicine. BMJ (1998) 1.74
The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (1998) 1.71
1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension (1989) 1.70
Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas. Arch Dermatol (1990) 1.70
Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet (1993) 1.67
Interventional bronchoscopy for tuberculous tracheobronchial stenosis. Eur Respir J (2004) 1.66
Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med (2010) 1.65
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med (1996) 1.64
Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol (2001) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (2000) 1.60
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother (1998) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1999) 1.58
Pneumocystis carinii choroiditis after long-term aerosolized pentamidine therapy. Am J Ophthalmol (1990) 1.57
Catecholamines in fetal and newborn rat brain. J Neurochem (1973) 1.55
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Phosphatidic acid accumulation in the membranes of Escherichia coli mutants defective in CDP-diglyceride synthetase. J Biol Chem (1980) 1.53
A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest (1998) 1.51
Clinical comparison of isolator and BACTEC 660 resin media for blood culture. J Clin Microbiol (1990) 1.51
BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol (2001) 1.51
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med (1995) 1.46
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc (2000) 1.44
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS (1998) 1.43
Cloning and characterization of a Na+-driven anion exchanger (NDAE1). A new bicarbonate transporter. J Biol Chem (2000) 1.42
Trial of streptokinase in ischaemic stroke. Lancet (1995) 1.42
The commercial production of chemicals using pathway engineering. Biochim Biophys Acta (2000) 1.41
Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis (1995) 1.41
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther (1998) 1.40
Spatiotemporal evolution of Poiseuille-Rayleigh-Bénard flows in binary fluids with Soret effect under initial pulselike disturbances. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 1.40
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis (2000) 1.40
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Patterns of psychopathology among urban poor children: comorbidity and aggression effects. J Consult Clin Psychol (1996) 1.34
Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochem Biophys Res Commun (2005) 1.32
Comparative evaluation of four systems for determining susceptibility of gram-positive organisms. J Clin Microbiol (1986) 1.32
Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev (2002) 1.30
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis (1999) 1.30
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29